Introducing the Next Generation
Cancer Treatment

TAE Life Sciences has developed breakthrough technology for the clinical investigation of Boron Neutron Capture Therapy (BNCT) to provide a treatment option for patients with malignancies that are difficult to treat through traditional methods, such as head, neck and brain cancers. Our proprietary accelerator-based BNCT platform combines two well-known modalities - biological targeting and radiation therapy - for precision treatment at the cellular level. TAE Life Sciences now stands ready to bring this promising, previously inaccessible, treatment to hospital settings.

Benefits of TAE Life Sciences BNCT

Biologically
Targeted

Tumor cells absorb a safe, boron-based vector drug that, when combined with neutrons, reacts to preferentially kill those cells while limiting damage to healthy tissue.

Precision
Engineered

Our proprietary accelerator-based neutron beam can be tuned to patient-specific needs, delivering the lowest level of radiation with the greatest therapeutic impact.

Patient
Friendly

Boron Neutron Capture Therapy (BNCT) is typically delivered in one or two treatment sessions, limits damage to healthy tissue and fosters a higher quality of life.

Our Neutron Source

TAE Life Sciences is developing a state-of-the-art BNCT platform, the heart of which is an accelerator-based neutron source that is compact, cost-effective and precision engineered for optimum BNCT delivery.
  LEARN MORE  

* The device being developed by TAE Life Sciences is for investigational use only and has not been approved for sale or commercial use.

Clinical Partners

We are looking to partner with hospitals and research institutions to initiate clinical trials to validate the next generation of BNCT.

  LEARN MORE  
Investor Relations

TAE Life Sciences is interested in speaking with potential investors whose charter aligns with our mission.

  CONTACT US  

About Boron Neutron Capture Therapy

BNCT is a multi-step combination therapy. A cancer patient is first administered a boron target drug that preferentially binds to and carries non-toxic boron-10 to malignant cells. The tumor tissue is then showered with a beam of low energy neutrons at a level and spectrum optimal for reaction with the boron-10.

This reaction, inside the cells, emits charged particles that destroy the cell while limiting damage to surrounding healthy tissue without boron-10. Once the beam reacts with the boron in the cancer cells, the relative biological effectiveness (RBE) is many times greater than traditional radiation therapies.

This secondary radiation reaction, with cellular-level precision, spares more healthy tissue and can potentially treat cancers that otherwise have few treatment options due to their proximity to critical tissue.